Flyer

Health Science Journal

  • ISSN: 1108-7366
  • Journal h-index: 61
  • Journal CiteScore: 17.30
  • Journal Impact Factor: 18.23
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • CINAHL Complete
  • Scimago
  • Electronic Journals Library
  • Directory of Research Journal Indexing (DRJI)
  • EMCare
  • OCLC- WorldCat
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • SHERPA ROMEO
  • Secret Search Engine Labs
Share This Page

Treatment with Anti SARS-COV2 Monoclonal Antibodies: Experience in Internal Medicine

XX Congresso Regionale FADOI CAMPANIA: Non ci siamo mai fermati
Italy 2021

Costume A, Scognamiglio G, Meini G and Ranucci RAN

U.O.C. Internal Medicine, P.O. â�?S.Maria delle Grazieâ�?, Pozzuoli (NA), Italy

Posters & Accepted Abstracts: Health Sci J

Abstract:

Background and aims: FDA authorized emergency monoclonal antibodies use in the early phase of the COVID disease because it’s associated to reduction of viral load, access in emergency room, hospitalization and mortality. The scientific technical committee set up specific administration center called MABS in the hospitals to improve clinical experience. Materials and methods: From 03.29.2021 a new MABS Center is enabled in our Hospital for frail patients (Table 1) up to 12 years old, with mild to moderate forms of illness in the tenth day from the beginning of the disease, not hospitalized, without need of oxygen, with at least one of risk factors as in the table. Until 07.30.2021 out of a total of 30,000 infected patients, 176 have been reported to the ASL. Of these only 116 were mostly indicated for the treatment. Results: Of these 116 patients eleven adverse events are reported: one death (0.86%), nine hospitalized patients (7.75%), one hospitalization non-COVID related (0.86%). Discussion: MABS in early phase of the COVID disease are very efficacy and their use is likely useful in recovered patients.